长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效观察

目的探讨长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床疗效。方法将60例晚期非小细胞肺癌患者随机分为观察组和对照组,每组各30例,观察组给予长春瑞滨联合顺铂治疗,对照组给予长春瑞滨治疗,比较两组患者的临床疗效。结果观察组和对照组的总有效率分别为96.67%和70.00%,观察组疗效明显优于对照组,两组差异有统计学意义(P<0.05)。结论长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效显著,不良反应少,容易耐受,值得临床推广和应用。

Clinical Curative effects of Vinorelbine unites Cisplati Treating Later Period Non-small Cell Lung Cancer

Objective Discusses Vinorelbine unite Cisplati treatment later period non-small cell lung cancer clinical curative effects.Methods Divided into the observation group and control group each 30 examples stochastically 60 examples later period non-small cell lung cancer patients,the observation group gived Vinorelbine unite Cisplati treatments,the control group gived Vinorelbine treatment,compared two groups of patient′s clinical curative effects.Results The observation group and control group′s total effectiveness respectively were 96.67% and 70.00%,the observation group curative effect surpassed the control group obviously,two groups of comparisons,the difference had statistics significance(P<0.05).Conclusion Vinorelbine unites Cisplati treatment later period non-small cell lung cancer curative effects to be remarkable,responds not good few,easy to endure,is worth the clinical promotion and the application.